A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Status: Recruiting
Phase:
Diagnosis: Solid Tumor/Phase I
NCT ID: NCT01451632 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 11-307

 

The purpose of this study is to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.

 

Conducting Institutions:
Dana-Farber Cancer Institute

Overall PI:
James Cleary M.D.,Ph.D., Dana-Farber Cancer Institute

Site-responsible Investigators:

Contacts:
Dana-Farber Cancer Institute: Linda Pointon, 617-632-4391, linda_pointon@dfci.harvard.edu

Eligibility Criteria

Inclusion Criteria: - No standard options remaining - Adequate liver and kidney functions - 18 years of age or above Exclusion Criteria: - History of any secondary active cancer in the last 3 years. - Pregnant or breast feeding - History of severe allergic reactions or contraindications to cetuximab or irinotecan
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms